clinical trial · NCT06806137
A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age
GlaxoSmithKline·phase3·recruiting·n = 600
ChickenpoxInvestigational varicella vaccineMarketed varicella vaccineMMR vaccineHepatitis A vaccinePCV (pneumococcal conjugate vaccine) 13PCV 20Vaxneuvance
brief summary
The purpose of this study is to evaluate the immune response and safety of GSKs investigational varicella vaccine (VNS Vaccine) compared to an already approved varicella vaccine, Varivax (VV), when administered as second dose to healthy children. 3 months after first dose at 12 to 15 months. The study will be conducted in children who have not previously contracted varicella or received a varicella vaccination.
started
May 15, 2025
primary completion
Dec 14, 2026
completion
May 3, 2027
last updated
Dec 4, 2025
official title
A Phase 3a, Observer-blind, Randomized, Controlled, Study to Evaluate the Immunogenicity and Safety of an Investigational Varicella Vaccine Compared With Varivax, When Given as a Second Dose to Healthy Children, 3 Months After the Administration of a First Dose at 12 to 15 Months of Age
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol